ArticleFrontiers in medicine2025
Longitudinal assessment of liver stiffness and risk factors for advanced fibrosis in adolescents with metabolic dysfunction-associated steatotic liver disease: a retrospective observational study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents is steadily increasing. This research aims to characterize adolescents diagnosed with MASLD clinically and evaluate their long-term outcomes in community and tertiary medical centers located in Shanghai. Furthermore, the investigation assesses the diagnostic efficacy of vibration-controlled transient elastography (VCTE) among adolescents with MASLD. Methods: We retrospectively analyzed data from adolescent patients (10-18 years) diagnosed with MASLD referred to Shanghai hospitals during the period 2019-2023. Diagnostic criteria included sustained alanine transaminase elevations exceeding twice the upper normal threshold or radiological confirmation of hepatic steatosis, following exclusion of alternative etiologies. VCTE-derived liver stiffness measurements (LSMs) were classified as normal (≤7.0 kPa, F0-F1), significant fibrosis (7.1-9.0 kPa, F2), and advanced fibrosis (≥9.1 kPa, F3-F4), to distinguish fibrosis severity. Results: A total of 140 adolescents were enrolled (67.9% male), with an average age of 13.8 years. Dyslipidemia was common (48.6%; Conclusion: There is a rapid increase in adolescent MASLD incidence in Shanghai. According to LSM assessments, adolescents diagnosed with MASLD may have heightened risks of advanced hepatic fibrosis as they approach late adolescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.